Efficacy and Safety of Alpha-2 Agonists in Autism Spectrum Disorder: A Systematic Review

IF 3.4 3区医学 Q2 MEDICINE, RESEARCH & EXPERIMENTAL

Advances in Therapy Pub Date : 2024-09-13 DOI:10.1007/s12325-024-02980-0

Alan D. Kaye, Abigail M. Green, Joseph Tremblay Claude II, Charles P. Daniel, Jada F. Cooley, Kelly R. Sala, Pooja Potharaju, Ross Rieger, Shilpadevi Patil, Shahab Ahmadzadeh, Sahar Shekoohi

{"title":"Efficacy and Safety of Alpha-2 Agonists in Autism Spectrum Disorder: A Systematic Review","authors":"Alan D. Kaye, Abigail M. Green, Joseph Tremblay Claude II, Charles P. Daniel, Jada F. Cooley, Kelly R. Sala, Pooja Potharaju, Ross Rieger, Shilpadevi Patil, Shahab Ahmadzadeh, Sahar Shekoohi","doi":"10.1007/s12325-024-02980-0","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><p>This analysis is a systematic literature review assessing efficacy and adverse effects of three alpha-2 agonists for the symptomatic management of autism spectrum disorder (ASD).</p><h3>Methods</h3><p>The present investigation involved an extensive systematic search for eligible studies in PubMed, Embase, Cochrane Library, and Google Scholar. Nine studies, collectively incorporating 226 patients, were assessed.</p><h3>Results</h3><p>The results demonstrated promising indications for use of alpha-2 agonists in the symptomatic management of autism spectrum disorders, including improvement of hyperactivity, impulsivity, attention deficit symptoms, irritability, and stereotypies in many of the participants studied.</p><h3>Conclusion</h3><p>The present investigation encourages physicians to consider treatment outcomes of clonidine, guanfacine, and lofexidine to determine the most effective management of ASD-related symptoms and to minimize adverse effects. However, our review cannot provide definitive treatment protocols related to various study limitations.</p></div>","PeriodicalId":7482,"journal":{"name":"Advances in Therapy","volume":"41 11","pages":"4299 - 4311"},"PeriodicalIF":3.4000,"publicationDate":"2024-09-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Advances in Therapy","FirstCategoryId":"3","ListUrlMain":"https://link.springer.com/article/10.1007/s12325-024-02980-0","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}

引用次数: 0

Abstract

Background

This analysis is a systematic literature review assessing efficacy and adverse effects of three alpha-2 agonists for the symptomatic management of autism spectrum disorder (ASD).

Methods

The present investigation involved an extensive systematic search for eligible studies in PubMed, Embase, Cochrane Library, and Google Scholar. Nine studies, collectively incorporating 226 patients, were assessed.

Results

The results demonstrated promising indications for use of alpha-2 agonists in the symptomatic management of autism spectrum disorders, including improvement of hyperactivity, impulsivity, attention deficit symptoms, irritability, and stereotypies in many of the participants studied.

Conclusion

The present investigation encourages physicians to consider treatment outcomes of clonidine, guanfacine, and lofexidine to determine the most effective management of ASD-related symptoms and to minimize adverse effects. However, our review cannot provide definitive treatment protocols related to various study limitations.

Abstract Image

查看原文本刊更多论文

阿尔法-2 受体激动剂对自闭症谱系障碍的疗效和安全性：系统回顾

背景本分析报告是一篇系统性文献综述，评估了三种α-2激动剂用于自闭症谱系障碍（ASD）对症治疗的疗效和不良反应。结果研究结果表明，α-2 受体激动剂在自闭症谱系障碍的对症治疗中具有良好的适应症，包括改善许多受试者的多动、冲动、注意力缺陷症状、易激惹和刻板行为。结论本调查鼓励医生考虑氯尼定、胍法辛和洛非西定的治疗效果，以确定最有效的自闭症谱系障碍相关症状治疗方法，并最大限度地减少不良反应。然而，由于各种研究的局限性，我们的综述无法提供明确的治疗方案。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Advances in Therapy 医学-药学

CiteScore

7.20

自引率

2.60%

发文量

353

审稿时长

6-12 weeks

期刊介绍： Advances in Therapy is an international, peer reviewed, rapid-publication (peer review in 2 weeks, published 3–4 weeks from acceptance) journal dedicated to the publication of high-quality clinical (all phases), observational, real-world, and health outcomes research around the discovery, development, and use of therapeutics and interventions (including devices) across all therapeutic areas. Studies relating to diagnostics and diagnosis, pharmacoeconomics, public health, epidemiology, quality of life, and patient care, management, and education are also encouraged. The journal is of interest to a broad audience of healthcare professionals and publishes original research, reviews, communications and letters. The journal is read by a global audience and receives submissions from all over the world. Advances in Therapy will consider all scientifically sound research be it positive, confirmatory or negative data. Submissions are welcomed whether they relate to an international and/or a country-specific audience, something that is crucially important when researchers are trying to target more specific patient populations. This inclusive approach allows the journal to assist in the dissemination of all scientifically and ethically sound research.